Efficacy and Safety of PSCK9 Inhibitors on Patients with Acute Coronary Syndrome: A Systematic Review and Meta-Analysis of Randomised Controlled Trials

Efficacy and Safety of PSCK9 Inhibitors on Patients with Acute Coronary Syndrome: A Systematic Review and Meta-Analysis of Randomised Controlled Trials

Background: PCSK9 MaB (Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor) may reduce the occurrence of major adverse cardiovascular events (MACEs) in patients diagnosed with acute coronary syndrome (ACS). In this meta-analysis, we conducted a thorough compilation of evidence from established c...

Full description

Bibliographic Details
Main Authors: Jiajing Zhao, Xinyu Tong, Jian Peng, Chuxin Lyu, Shu Lu
Format: Article
Language:English
Published: IMR Press 2024-03-01
Series:Reviews in Cardiovascular Medicine
Subjects:
psck9i
acute coronary syndrome
systematic review
meta-analysis
Online Access:https://www.imrpress.com/journal/RCM/25/3/10.31083/j.rcm2503094

Internet

https://www.imrpress.com/journal/RCM/25/3/10.31083/j.rcm2503094

Similar Items